Home › Calculator › BMY Dividend Calculator 2026
BMY Dividend DRIP Calculator 2026
4.23% YieldHealthcareBristol-Myers Squibb Company · NYSE
Price: $59.58 · Annual div: $2.52/share · Frequency: quarterly · Payout ratio: 73% · Ex-div: 2026-10-02
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BMY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your BMY snowball 📈
$10,000 in BMY → $24.6K in 10 years · $99.65/month
About Bristol-Myers Squibb Company (BMY) — Dividend Analysis 2026
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Compare BMY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BMY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BMY position with:
🌍 BMY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BMY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 4.23% | 1.43% | $423 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3.60% | 0.80% | $360 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 3.38% | 0.58% | $338 / yr |
| 🇬🇧 UK ISA | 0% | 4.23% | 1.43% | $423 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3.86% | 1.06% | $386 / yr |
| 🇨🇦 TFSA | 0% | 4.23% | 1.43% | $423 / yr |
| 🇨🇦 CA Taxable | 25% | 3.17% | 0.37% | $317 / yr |
| 🇦🇺 Super (pension) | 15% | 3.60% | 0.80% | $360 / yr |
| 🇦🇺 AU Taxable | 30% | 2.96% | 0.16% | $296 / yr |
| 🇩🇪 DE Taxable | 26.375% | 3.11% | 0.31% | $311 / yr |
| 🇫🇷 FR Taxable | 30% | 2.96% | 0.16% | $296 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BMY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.52/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BMY Dividend Payment Schedule
BMY pays quarterly — 4 times per year. Ex-div: 2026-10-02.
📊 BMY vs Healthcare Benchmarks
How BMY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BMY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BMY Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-10-02 | 4,559 | — | — | ||
| F-InKind | 2026-10-02 | 2,332 | $61.15 | $142.6K | ||
| M-Exempt | 2026-10-02 | 4,559 | — | — | ||
| A-Award | 2026-09-30 | 560.897 | — | — | ||
| A-Award | 2026-09-30 | 821.314 | — | — | ||
| A-Award | 2026-09-30 | 620.994 | — | — | ||
| A-Award | 2026-09-30 | 560.897 | — | — | ||
| A-Award | 2026-09-30 | 560.897 | — | — | ||
| Sale | 2026-09-09 | 6,249 | $64.57 | $403.5K | ||
| M-Exempt | 2026-09-01 | 1,236 | $66.92 | $82.7K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare BMY with peers: BMY vs CI · BMY vs CVS · BMY vs ELV
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where BMY earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BMY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Bristol-Myers Squibb Company (BMY) is currently trading at $59.58, 13% below its 52-week high. The current dividend yield is 4.23% based on an annual payout of $2.52 per share.
Bristol-Myers Squibb Offers Solid Yield with Manageable Payouts
AI SummaryBristol-Myers Squibb Company provides a compelling 4.23% dividend yield backed by a manageable 73% payout ratio, striking a reasonable balance between rewarding shareholders and retaining capital for business needs. The company's conservative valuation, reflected in a 17.3 P/E ratio, and a solid five-year dividend CAGR of 6.5% highlight its historical commitment to steady income growth within the healthcare sector. However, sustaining this trajectory requires careful navigation of upcoming patent expirations for key blockbuster drugs. While current cash flows comfortably cover the $2.52 annual dividend, future growth depends heavily on the successful commercialization of its newer product pipeline to offset anticipated revenue declines from older medications.
- Patent expirations on major blockbuster drugs
- Pipeline execution and replacement of lost revenue
Generated by AI using live market data. For educational purposes only — not financial advice.
Latest BMY News
LiveHow investors use the BMY dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.